AAAAAA

   
Results: 1-23 |
Results: 23
The Chk1-Cdc25C regulation is involved in sensitizing A253 cells to a novel topoisomerase I inhibitor BNP1350 by bax gene transfer
Authors: Yin, MB Hapke, G Guo, B Azrak, RG Frank, C Rustum, YM
Citation: Mb. Yin et al., The Chk1-Cdc25C regulation is involved in sensitizing A253 cells to a novel topoisomerase I inhibitor BNP1350 by bax gene transfer, ONCOGENE, 20(38), 2001, pp. 5249-5257
Irinotecan in the treatment of colorectal cancer: Clinical overview
Authors: Vanhoefer, U Harstrick, A Achterrath, W Cao, SS Seeber, S Rustum, YM
Citation: U. Vanhoefer et al., Irinotecan in the treatment of colorectal cancer: Clinical overview, J CL ONCOL, 19(5), 2001, pp. 1501-1518
Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma
Authors: Guo, B Cao, SS Toth, K Azrak, RG Rustum, YM
Citation: B. Guo et al., Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma, CLIN CANC R, 6(2), 2000, pp. 718-724
Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity inpatients with metastatic cancer
Authors: Ho, DH Covington, W Brown, N Lin, SN Pazdur, R Huo, YY Creaven, PJ Rustum, YM Meropol, NJ Lassere, Y Kuritani, J Hayakawa, T
Citation: Dh. Ho et al., Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity inpatients with metastatic cancer, CANC CHEMOT, 46(5), 2000, pp. 351-356
Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells
Authors: Minderman, H Wrzosek, C Cao, SS Utsugi, T Kobunai, T Yamada, Y Rustum, YM
Citation: H. Minderman et al., Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells, CANC CHEMOT, 45(1), 2000, pp. 78-84
Time-lapse video reveals immediate heterogeneity and heritable damage among human ileocecal carcinoma HCT-8 cells treated with raltitrexed (ZD1694)
Authors: Slocum, HK Parsons, JC Winslow, EO Broderick, L Minderman, H Toth, K Greco, WR Rustum, YM
Citation: Hk. Slocum et al., Time-lapse video reveals immediate heterogeneity and heritable damage among human ileocecal carcinoma HCT-8 cells treated with raltitrexed (ZD1694), CYTOMETRY, 41(4), 2000, pp. 252-260
Preclinical development of eniluracil: Enhancing the therapeutic index anddosing convenience of 5-fluorouracil
Authors: Paff, MT Baccanari, DP Davis, ST Cao, SS Tansik, RL Rustum, YM Spector, T
Citation: Mt. Paff et al., Preclinical development of eniluracil: Enhancing the therapeutic index anddosing convenience of 5-fluorouracil, INV NEW DR, 18(4), 2000, pp. 365-371
Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: Role of drug sequence anddose
Authors: Cao, SS Rustum, YM
Citation: Ss. Cao et Ym. Rustum, Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: Role of drug sequence anddose, CANCER RES, 60(14), 2000, pp. 3717-3721
alpha-fluoro-beta-alanine: Effects on the antitumor activity and toxicity of 5-fluorouracil
Authors: Cao, SS Baccanari, DP Rustum, YM Davis, ST Tansik, RL Porter, DJT Spector, T
Citation: Ss. Cao et al., alpha-fluoro-beta-alanine: Effects on the antitumor activity and toxicity of 5-fluorouracil, BIOCH PHARM, 59(8), 2000, pp. 953-960
Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: Role of dosing schedule and plasma thymidine
Authors: Cao, SS McGuire, JJ Rustum, YM
Citation: Ss. Cao et al., Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: Role of dosing schedule and plasma thymidine, CLIN CANC R, 5(7), 1999, pp. 1925-1934
Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model
Authors: Cao, SS Lu, K Toth, K Slocum, HK Shirasaka, T Rustum, YM
Citation: Ss. Cao et al., Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model, CLIN CANC R, 5(2), 1999, pp. 267-274
Dimerization of mitochondrial Bax is associated with increased drug response in Bax-transfected A253 cells
Authors: Guo, B Yin, MB Toth, K Cao, SS Azrak, RG Rustum, YM
Citation: B. Guo et al., Dimerization of mitochondrial Bax is associated with increased drug response in Bax-transfected A253 cells, ONCOL RES, 11(2), 1999, pp. 91-99
Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: Mechanisms and clinical implications
Authors: Matsui, SI Endo, W Wrzosek, C Haridas, K Seetharamulu, P Hausheer, FH Rustum, YM
Citation: Si. Matsui et al., Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: Mechanisms and clinical implications, EUR J CANC, 35(6), 1999, pp. 984-993
Clinical implications of 5-FU modulation
Authors: Rustum, YM
Citation: Ym. Rustum, Clinical implications of 5-FU modulation, ONCOLOGY-NY, 13(7), 1999, pp. 22-25
Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: A potential role for growth factor as mucosal protectant
Authors: Meropol, NJ Rustum, YM Creaven, PJ Blumenson, LE Frank, C
Citation: Nj. Meropol et al., Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: A potential role for growth factor as mucosal protectant, CANCER INV, 17(1), 1999, pp. 1-9
Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer
Authors: Vanhoefer, U Harstrick, A Kohne, CH Achterrath, W Rustum, YM Seeber, S Wilke, H
Citation: U. Vanhoefer et al., Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer, J CL ONCOL, 17(3), 1999, pp. 907-913
New drugs in therapy of colorectal cancer: Preclinical studies
Authors: Rustum, YM Cao, SS
Citation: Ym. Rustum et Ss. Cao, New drugs in therapy of colorectal cancer: Preclinical studies, SEMIN ONCOL, 26(6), 1999, pp. 612-620
Involvement of cyclin D1-CDK5 overexpression and MCM3 cleavage in bax-associated spontaneous apoptosis and differentiation in an A253 human head and neck carcinoma xenograft model
Authors: Yin, MB Toth, K Cao, SS Guo, B Frank, C Slocum, HK Rustum, YM
Citation: Mb. Yin et al., Involvement of cyclin D1-CDK5 overexpression and MCM3 cleavage in bax-associated spontaneous apoptosis and differentiation in an A253 human head and neck carcinoma xenograft model, INT J CANC, 83(3), 1999, pp. 341-348
Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex
Authors: Yin, MB Guo, B Panadero, A Frank, C Wrzosek, C Slocum, HK Rustum, YM
Citation: Mb. Yin et al., Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex, EXP CELL RE, 247(1), 1999, pp. 189-199
Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines
Authors: Vanhoefer, U Muller, MR Hilger, RA Lindtner, B Klaassen, U Schleucher, N Rustum, YM Seeber, S Harstrick, A
Citation: U. Vanhoefer et al., Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines, BR J CANC, 81(8), 1999, pp. 1304-1310
Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin-6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034) - Comparison across sensitive and resistant human tumor cell lines
Authors: Faessel, HM Slocum, HK Rustum, YM Greco, WR
Citation: Hm. Faessel et al., Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin-6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034) - Comparison across sensitive and resistant human tumor cell lines, BIOCH PHARM, 57(5), 1999, pp. 567-577
Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis
Authors: Voigt, W Matsui, S Yin, MB Burhans, WC Minderman, H Rustum, YM
Citation: W. Voigt et al., Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis, ANTICANC R, 18(5A), 1998, pp. 3499-3505
Modeling of the time-dependency of in vitro drug cytotoxicity and resistance
Authors: Levasseur, LM Slocum, HK Rustum, YM Greco, WR
Citation: Lm. Levasseur et al., Modeling of the time-dependency of in vitro drug cytotoxicity and resistance, CANCER RES, 58(24), 1998, pp. 5749-5761
Risultati: 1-23 |